PURE Bioscience, Inc. (PURE) Gross margin 2017–2026
PURE Bioscience, Inc. (PURE) gross margin by fiscal year — reported gross profit divided by reported revenue.
57.2%FY2026 · since FY2017: 58.5% → 57.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 57.2% | -2.0 pp |
| FY2025 | 59.2% | +0.5 pp |
| FY2024 | 58.7% | +7.0 pp |
| FY2023 | 51.7% | -2.2 pp |
| FY2022 | 54.0% | +1.1 pp |
| FY2021 | 52.8% | -5.3 pp |
| FY2020 | 58.1% | -3.7 pp |
| FY2019 | 61.9% | +4.9 pp |
| FY2018 | 57.0% | -1.5 pp |
| FY2017 | 58.5% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PURE financial trends
PURE RevenuePURE Net incomePURE Net marginPURE Gross profitPURE Operating incomePURE Operating marginPURE Operating cash flowPURE Free cash flowPURE Capital expendituresPURE Return on equityPURE Stock buybacksPURE Dividends paidPURE Total assetsPURE Total liabilitiesPURE Shareholders’ equityPURE overview →